IL6 and cancer: Nonetheless, it would be interesting to evaluate whether, beyond IL-6 blockade, senescent cell ablation might also ameliorate the efficacy of cancer treatment modalities by impeding the replenishment of treatment-refractory CSCs that might de novo arise by cellular reprogramming-like phenomena of non-CSC tumor counterparts.